311nm窄谱中波紫外线照射治疗寻常性银屑病疗效观察

目的观察311nm窄谱中波紫外线(NB-UVB)照射治疗寻常性银屑病的疗效及其影响因素。方法单独采用NB-UVB照射或联合糠馏油硼酸氧化锌软膏(PBZS)封包治疗寻常性银屑病87例,并以银屑病面积和严重度指数(PASI)评价疗效,分析性别、皮肤类型、临床分型及临床分期对疗效的影响,同时对采用其他方法治疗的30例寻常性银屑病患者进行回顾性的评价。结果在(17.60±4.42)d、(16.90±5.80)d、(25.80±6.67)d治疗后,NB-UVB组、NB-UVB+PBZS组及回顾分析组治疗前后PASI评分改善率分别为(76.3±24.6)%、(88.1±28.7)%、(76.5±26.2)%;与回顾分析组比较,NB-UVB组与其疗效相当(P>0.05),但治疗时间显著缩短(P<0.05),而NB-UVB+PBZS组则在更短的治疗时间(P<0.05)取得了更好的疗效(P<0.05);疗效相关因素分析表明,点滴状略优于斑块状、进行期略优于静止期(0.01相似文献   

窄谱中波紫外线治疗寻常型银屑病临床疗效观察

近10余年来，国外利用窄谱中波紫外线(NB-UVB，波长311～313nm)照射治疗银屑病，该疗法等同或甚至优于补骨脂素长波紫外线(PUVA)的疗效，而且较PUVA安全，因此临床应用日渐增多。为了探索NB-UVB对我国银屑病患者的疗效影响，自2002年10月起，笔者对40例寻常型银屑病患者采用NB-UVB全身照射并进行临床观察，现报告如下。     

阿维A联合窄谱中波紫外线照射治疗寻常型银屑病疗效观察

目的:观察阿维A联合窄谱中波紫外线(NB-uVB)照射治疗寻常型银屑病的临床疗效及影响因素.方法:单独采用NB-uVB照射或联合口服阿维A治疗银屑病70例,并以银屑病面积和严重指数(PAsI)评价疗效,分析性别、皮肤类型、临床亚型及分期对疗效的影响.结果:窄谱中波紫外线照射治疗银屑病有效,联合口服阿维A后疗效可显著提高,缩短疗程,疗效相关因素分析表明,进行期优于静止期(P＜0.05),点滴型优于斑块型(P＜0.05),Ⅲ型皮肤优于Ⅳ型皮肤(P＜0.05),但男性略优于女性(P＞0.05).结论:NB-uVB照射治疗寻常型银屑病疗效好,不良反应小,结合口服阿维A能显著增加疗效,其疗效可能与寻常型银屑病亚型、分期及患者皮肤类型有关.     

窄谱中波紫外线治疗寻常型银屑病疗效观察

近10年来，国内外采用窄谱中波紫外线（NB-UVB）照射治疗银屑病，取得了较好的临床疗效。2004年2月始，我院对64例寻常型银屑病患者采用NB-UVB全身照射治疗，并进行临床疗效观察，现报道如下。     

窄谱中波紫外线治疗寻常型银屑病2087例疗效观察

目的观察窄谱中波紫外线(NB-UVB)治疗寻常型银屑病的临床疗效及安全性。方法回顾性分析采用NB-UVB治疗2087例银屑病患者的有效率,治疗频次及不良反应等。结果NB-UVB治疗寻常型银屑病有效率为84.20%,平均治疗频次17.6次,不良反应以灼烧感、红斑、瘙痒为主。结论NB-UVB治疗寻常型银屑病,安全有效,患者依从性高,但其疗效与寻常型银屑病的分期及分型有关。     

窄谱中波紫外线治疗寻常型银屑病疗效观察

窄谱中波紫外线（NB-UVB波长311-313nm）照射治疗银屑病，该疗法等同或优于补骨脂素长波紫外线（PUVA）疗法，而且较PUVA安全，因此近年来临床应用渐多。我科自2005年5月以来采用NB-UVB治疗寻常型银屑病61例，取得满意疗效，现将观察结果总结如下。     

中草药煎服配合窄谱中波紫外线照射治疗寻常型银屑病疗效观察

目的:观察中草药煎服配合窄谱中波紫外线(NB-UVB)治疗寻常型银屑病的疗效.方法:将寻常型银屑病患者随机分成3组,治疗组以中草药煎服配合NB-UVB照射同时进行;对照1组仅用中草药煎服;对照2组仅用NB-uVB照射.此3组中有咽喉红肿者加罗红霉素胶囊口服.结果:治疗组有效率明显高于对照1组和对照2组(χ2值分别为11.03和11.49,均P＜0.05).结论:中草药煎服配合NB-uVB治疗寻常型银屑病疗效好.     

窄谱中波紫外线治疗寻常型银屑病临床观察

为观察窄谱中波紫外线照射治疗寻常型银屑病的疗效及安全性,我们使用窄谱中波紫外线照射治疗寻常型银屑病42例。结果:痊愈16例,显效20例,有效6例。总有效率85.7%,平均照射次数21.4次,平均照射剂量30.5 J/cm2。不良反应主要表现为轻度红斑、瘙痒及色素沉着。窄谱中波紫外线照射治疗寻常型银屑病疗效好、不良反应少、易于操作、患者易于接受。     

窄谱中波紫外线治疗寻常型银屑病临床疗效观察

2003～2005年我们采用窄谱中波紫外线（NB—UVB）照射治疗寻常型银屑病58例，观察其对不同皮损表现的寻常型银屑病的治疗效果及安全性，现将结果报道如下。     

窄谱中波紫外线照射联合复方甘草酸单铵治疗寻常型银屑病疗效观察

目的观察窄谱中波紫外线治疗银屑病的,临床疗效及安全性。方法将60例银屑病患者随机分为治疗组与对照组,两组均给予复方甘草酸单铵治疗,治疗组辅以窄谱中波紫外线照射。初始剂量0．4J／cm2。每次增加剂量0．05～0．1J／cm2,每周3次,连续28次,总疗程约2个月。结果治疗组30例基本痊愈8例,显效16例,有效4例,无效2例,对照组30例基本痊愈2例,显效9例,有效15例,无效3例,治疗组总有效率高于对照组（P〈0．05）。不良反应主要为不同程度的皮肤变黑、干燥、脱屑或瘙痒。结论窄谱中波紫外线照射治疗银屑病安全、有效。     

补骨脂素长波紫外线和窄谱中波紫外线治疗寻常性银屑病临床疗效观察

目的:观察补骨脂素长波紫外线(PUVA)和窄谱中波紫外线(NB-UVB)治疗寻常性银屑病的临床疗效及其影响因素。方法:分别采用PUVA和311nmNB-UVB照射治疗146例寻常性银屑病患者,并以银屑病面积和严重度指数(PASI)评价疗效,分析照射剂量等对疗效和复发的影响。结果:NB-UVB治疗寻常性银屑病的疗效与PUVA相当,NB-UVB组患者的治疗时间明显短于PUVA组,NB-UVB组患者1年内复发率高于PUVA组。结论:NB-UVB治疗寻常性银屑病与PUVA相比,不良反应较少,起效较快。     

A single blind randomized clinical study: the efficacy of isotretinoin plus narrow band ultraviolet B in the treatment of psoriasis vulgaris

In this randomized clinical trial, 39 patients with psoriasis vulgaris were randomized in two groups. Intervention group received narrow band ultraviolet B (NBUVB)+isotretinoin (0.5 mg/kg/day), control group received NBUVB+placebo. Psoriasis Area Severity Index (PASI) scoring was recorded at baseline and weeks 4, 10, and 14. Thirty‐seven patients completed the study. According to recorded PASI scores the difference between efficacies of two treatments was not significant. Complete clearing was noticed in 14 and 13 patients in intervention group and controls. The mean cumulative NBUVB dose in intervention group and controls was 29.95 ± 16.11 vs. 45.77 ± 7.72 J/cm² (P=0.004). Isotretinoin+NBUVB can reduce number of phototherapy sessions and cumulative NBUVB dose.     

Bath psoralen+ultraviolet A photochemotherapy vs. narrow band‐ultraviolet B in psoriasis: a comparison of clinical outcome and effect on circulating T‐helper and T‐suppressor/cytotoxic cells

Background: Comparative success rates of bath psoralen+ultraviolet A (PUVA) and narrow band‐ultraviolet B (NB‐UVB) in psoriasis treatment are variably reported with no previous studies on the possible effect of bath PUVA on circulating CD4+ and CD8+ T cells. Objective: We aimed to compare the effect of bath PUVA and NB‐UVB clinically and on circulating T‐helper and T‐suppressor/cytotoxic cells in psoriasis. Patients and methods: Thirty‐four psoriatic patients divided into a bath PUVA‐treated group (18 patients) and a NB‐UVB‐treated group (16 patients) were compared regarding the disease severity by psoriasis area and severity index (PASI) score and percentage of circulating CD4+ and CD8+ T cells by flowcytometry before and after treatment. Results: After treatment, the bath PUVA group showed a significantly higher reduction of PASI score (85.44%) than the NB‐UVB group (58.72%). Mean peripheral CD4+ T‐cell percentage was significantly lower after [36.8; 95% confidence interval (CI) 33.80, 39.97] compared with before treatment (42.06; 95% CI 38.29, 45.83) (P<0.05) in the bath PUVA group while this difference was insignificant in the NB‐UVB group (P>0.05). Conclusion: Bath PUVA therapy is superior to NB‐UVB in the treatment of moderate and severe psoriasis with mild reversible side effects. Both modalities have a systemic effect decreasing peripheral CD4+ T cells, which is more with bath PUVA.     

Langerhans cell histiocytosis treated with narrow-band ultraviolet B

A 58-year-old man had widespread multiple erythemas that had been untreated for 20 years. The cutaneous lesions increased in size for a year. Histopathological examination revealed increased number of large, dysplastic, histiocytic cells in the dermis; most of these cells tested positive for Langelin, CD1a and S-100 staining. The patient was diagnosed with Langerhans cell histiocytosis (LCH) and treated with narrow-band ultraviolet B (NB-UVB) radiation. The erythema improved after treatment, but the tumor remained. Therefore, the tumor was surgically excised. NB-UVB therapy might be effective for the treatment of superficial lesions, but not tumoral lesions of LCH.     

Two cases of eczematid‐like purpura of Doucas and Kapetanakis responsive to narrow band ultraviolet B treatment

Eczematid‐like purpura of Doucas and Kapetanakis is a type of pigmented purpuric dermatoses (PPDs) with eczematous changes in the purpuric surface. A 10‐year‐old male and a 44‐year‐old male patients were admitted to our clinics for itching and flaking of the skin rashes. Based on the clinical and histopathological evaluations, the rashes were identified as eczematid‐like PPDs of Doucas and Kapetanakis. Both patients were treated with narrow band ultraviolet B. The lesions were remarkably regressed following the treatment. These cases reported due its rarity and good response to narrow band ultraviolet B.     

他扎罗汀凝胶外用联合NB-UVB治疗斑块状寻常型银屑病的疗效观察

目的：观察他扎罗汀凝胶外用联合NB-UVB照射治疗斑块状寻常型银屑病的疗效及安全性。方法：对35例轻、中度患者采用0．05％他扎罗汀凝胶每晚1次外涂配合NB-UVB每周2次照射，共治疗8周，用PASI积分评价疗效。结果：治疗开始1～2周后出现疗效，随着治疗时间的延长。有效率逐渐提高，治疗结束时痊愈率达到94．29％，有效率达100％。6例发生皮肤刺激反应，占17．14％。结论：他扎罗汀凝胶外用联合NB-UVB照射治疗斑块状寻常型银屑病具有良好疗效和安全性。     

Efficacy of ultraviolet B phototherapy for psoriasis in patients infected with human immunodeficiency virus

To evaluate the efficacy of ultraviolet B (UVB) phototherapy for the treatment of psoriasis in patients infected with human immunodeficiency virus (HIV), the response of 14 patients was compared to that of matched seronegative control individuals. All patients were evaluated prior to treatment (baseline) and after 21 treatments for the extent of total body surface area (TBSA) involvement and the quantification of scale, erythema, and thickness of plaques using a scale of 0 (absent) to 4 (severe). The only concomitant medication allowed was salicylic acid in petrolatum. The cumulative score for scale, erythema, and thickness improved 1.9± 0.5 [mean± standard error of mean (SEM)] in the HIV group and 2.4± 0.3 in controls. There was 40.9± 7.3 % reduction of TBSA involvement in the former and 38.4± 7.6 % reduction in the latter group. None of the differences was statistically significant. There was no statistically significant difference in the response to therapy among various stages of immunosuppression in the HIV group. There was also no deterioration of immune status in this group. UVB phototherapy is an effective treatment for psoriasis in patients infected with HIV. The response is identical to that of matched control individuals.     

Topical 8-methoxypsoralen increases the efficacy of narrowband ultraviolet B in psoriasis

Background: A combination of oral psoralen with narrowband ultraviolet B (UVB), defined as 'psoralen-narrowband UVB', was shown to have a superior efficacy than UVB alone and even a comparable efficacy to psoralen and ultraviolet A in psoriasis.
Objective: To find out whether topical psoralen-narrowband UVB provides any additional benefit to narrowband UVB alone in psoriasis.
Methods: Nineteen patients with plaque psoriasis were included. Phototherapy was given three times per week. Two symmetrical lesions were selected as target lesions. In the first 12 sessions of phototherapy, the target lesion on one side was treated with 1% 8-methoxypsoralen (MOP) gel 30 min before UVB radiation whereas the target lesion on the other side served as a control. Target lesion scores were assessed at baseline, third, sixth, ninth and 12th sessions. Side effects were recorded.
Results: Sixteen patients completed the study. Target lesion scores decreased significantly on both sides ( P <0.0001). The mean percentage of decreases was greater on the 8-MOP-applied sides compared with the control sides for all assessments, but the difference was statistically significant only at the ninth session (37.7% vs. 58.6%, P =0.043). Pigmentation was frequently seen in 8-MOP gel-applied lesions.
Conclusion: Topical 8-MOP gel plus narrowband UVB has greater efficacy than narrowband UVB alone in psoriasis.